| pubmed-article:1654910 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1654910 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1654910 | lifeskim:mentions | umls-concept:C0004096 | lld:lifeskim |
| pubmed-article:1654910 | lifeskim:mentions | umls-concept:C0014806 | lld:lifeskim |
| pubmed-article:1654910 | lifeskim:mentions | umls-concept:C0085129 | lld:lifeskim |
| pubmed-article:1654910 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1654910 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:1654910 | pubmed:dateCreated | 1991-10-18 | lld:pubmed |
| pubmed-article:1654910 | pubmed:abstractText | The effects of erythromycin (erythromycin stearate, Erythromycin; CAS 643-22-1) on the bronchial hyperresponsiveness and the functions of lymphocytes and neutrophils were evaluated. Administration of erythromycin to asthmatic patients in a dosage of 600 mg/d for 10 weeks reduced the bronchial hyperresponsiveness measured by histamine inhalation test. Furthermore, incubation with erythromycin for 96 h inhibited the mixed lymphocyte reaction at the concentration of more than 10 mumol/l in a dose-dependent manner, and the value of IC50 was about 30 mumol/l. 2-h incubation with erythromycin showed a weak inhibition to n-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced superoxide production of polymorphonuclear neutrophils (PMNs) at the concentration of more than 30 mumol/l in a dose-dependent manner. 1-h incubation with 1 mumol/l and 100 mumol/l of erythromycin inhibited FMLP-induced chemotaxis of PMNs. The rates of inhibition at the concentration of 1 mumol/l and 100 mumol/l were 29.7% and 41.7%, respectively. Erythromycin thus showed a beneficial effect on bronchial hyperresponsiveness. This effect might be due to the regulation of the inflammatory cells. | lld:pubmed |
| pubmed-article:1654910 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1654910 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1654910 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1654910 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1654910 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1654910 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1654910 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1654910 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1654910 | pubmed:month | May | lld:pubmed |
| pubmed-article:1654910 | pubmed:issn | 0004-4172 | lld:pubmed |
| pubmed-article:1654910 | pubmed:author | pubmed-author:SuzukiKK | lld:pubmed |
| pubmed-article:1654910 | pubmed:author | pubmed-author:TakagiKK | lld:pubmed |
| pubmed-article:1654910 | pubmed:author | pubmed-author:SatakeTT | lld:pubmed |
| pubmed-article:1654910 | pubmed:author | pubmed-author:TakiFF | lld:pubmed |
| pubmed-article:1654910 | pubmed:author | pubmed-author:MiyatakeHH | lld:pubmed |
| pubmed-article:1654910 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1654910 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:1654910 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1654910 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1654910 | pubmed:pagination | 552-6 | lld:pubmed |
| pubmed-article:1654910 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:meshHeading | pubmed-meshheading:1654910-... | lld:pubmed |
| pubmed-article:1654910 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1654910 | pubmed:articleTitle | Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. | lld:pubmed |
| pubmed-article:1654910 | pubmed:affiliation | Second Department of Internal Medicine, Nagoya University School of Medicine, Japan. | lld:pubmed |
| pubmed-article:1654910 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1654910 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1654910 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1654910 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1654910 | lld:pubmed |
